Literature DB >> 17457974

Long-term outcome and prognostic factors of patients with hilar cholangiocarcinoma.

Andreas Weber1, Sonja Landrock, Jochen Schneider, Manfred Stangl, Bruno Neu, Peter Born, Meinhard Classen, Thomas Rösch, Roland-M Schmid, Christian Prinz.   

Abstract

AIM: To evaluate the long-term outcome and prognostic factors of patients with hilar cholangiocarinoma.
METHODS: Ninety-six consecutive patients underwent treatment for malignant hilar bile duct tumors during 1995-2005. Of the 96 patients, 20 were initially treated with surgery (n = 2 R0 / n = 18 R1). In non-operated patients, data analysis was performed retrospectively.
RESULTS: Among the 96 patients, 76 were treated with endoscopic transpapillary (ERC, n = 45) and/or percutaneous transhepatic biliary drainage (PTBD, n = 31). The mean survival time of these 76 patients undergoing palliative endoscopic and/or percutaneous drainage was 359 +/- 296 d. The mean survival time of patients with initial bilirubin levels > 10 mg/dL was significantly lower (P < 0.001) than patients with bilirubin levels < 10 mg/dL. The mean survival time of patients with Bismuth stage II (n = 8), III (n = 28) and IV (n = 40) was 496 +/- 300 d, 441 +/- 385 d and 274 +/- 218 d, respectively. Thus, patients with advanced Bismuth stage showed a reduced mean survival time, but the difference was not significant. The type of biliary drainage had no significant beneficial effect on the mean survival time (ERC vs PTBD, P = 0.806).
CONCLUSION: Initial bilirubin level is a significant prognostic factor for survival of patients. In contrast, age, tumor stage according to the Bismuth-Corlette classification, and types of intervention are not significant prognostic parameters for survival. Palliative treatment with endoscopic or percutaneous biliary drainage is still suboptimal, new diagnostic and therapeutic tools need to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17457974      PMCID: PMC4146927          DOI: 10.3748/wjg.v13.i9.1422

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Authors:  T Patel
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

2.  Management strategies in resection for hilar cholangiocarcinoma.

Authors:  H Bismuth; R Nakache; T Diamond
Journal:  Ann Surg       Date:  1992-01       Impact factor: 12.969

3.  A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma.

Authors:  T E Bowling; S M Galbraith; A R Hatfield; J Solano; M F Spittle
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

4.  Intrahepatic cholangiocarcinoma.

Authors:  K M Chu; E C Lai; S Al-Hadeedi; C E Arcilla; C M Lo; C L Liu; S T Fan; J Wong
Journal:  World J Surg       Date:  1997 Mar-Apr       Impact factor: 3.352

5.  Resection or palliation: priority of surgery in the treatment of hilar cancer.

Authors:  H Bismuth; D Castaing; O Traynor
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

6.  Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis.

Authors:  Kazuhiro Hanazaki; Shoji Kajikawa; Nobuhiko Shimozawa; Ko Shimada; Manabu Hiraguri; Naohiko Koide; Wataru Adachi; Jun Amano
Journal:  Hepatogastroenterology       Date:  2002 Mar-Apr

Review 7.  Cholangiocarcinoma.

Authors:  S A Ahrendt; A Nakeeb; H A Pitt
Journal:  Clin Liver Dis       Date:  2001-02       Impact factor: 6.126

8.  Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma.

Authors:  T Isa; T Kusano; H Shimoji; Y Takeshima; Y Muto; M Furukawa
Journal:  Am J Surg       Date:  2001-06       Impact factor: 2.565

9.  Bile duct carcinoma: trends in treatment in the nineties.

Authors:  D N Reed; G C Vitale; R Martin; H Bas; T J Wieman; G M Larson; M Edwards; K McMasters
Journal:  Am Surg       Date:  2000-08       Impact factor: 0.688

10.  Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study.

Authors:  Marianne E J Ortner; Karel Caca; Frieder Berr; Jochen Liebetruth; Ulrich Mansmann; Dominik Huster; Winfried Voderholzer; Guido Schachschal; Joachim Mössner; Herbert Lochs
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

View more
  12 in total

1.  Preoperative evaluation with T-staging system for hilar cholangiocarcinoma.

Authors:  Ru-Fu Chen; Zhi-Hua Li; Jia-Jia Zhou; Jie Wang; Ji-Sheng Chen; Qing Lin; Qi-Bing Tang; Ning-Fu Peng; Zhi-Peng Jiang; Quan-Bo Zhou
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

2.  Addition of hepatectomy decreases liver recurrence and leads to long survival in hilar cholangiocarcinoma.

Authors:  Zheng Shi; Ming-Zhi Yang; Qing-Liang He; Rong-Wen Ou; You-Ting Chen
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

3.  Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma.

Authors:  Mario Fernández-Ruiz; Juan-Manuel Guerra-Vales; Francisco Colina-Ruizdelgado
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

4.  Endoscopic transpapillary brush cytology and forceps biopsy in patients with hilar cholangiocarcinoma.

Authors:  Andreas Weber; Claus von Weyhern; Falko Fend; Jochen Schneider; Bruno Neu; Alexander Meining; Hans Weidenbach; Roland M Schmid; Christian Prinz
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

5.  Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study.

Authors:  Jongha Park; Myung-Hwan Kim; Kyu-Pyo Kim; Do Hyun Park; Sung-Hoon Moon; Tae Jun Song; Junbum Eum; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

6.  Primary patency of percutaneously inserted self-expanding metallic stents in patients with malignant biliary obstruction.

Authors:  Ursula Dahlstrand; Gabriel Sandblom; Lars-Gunnar Eriksson; Rickard Nyman; Ib Christian Rasmussen
Journal:  HPB (Oxford)       Date:  2009-06       Impact factor: 3.647

7.  Factors relating to the short term effectiveness of percutaneous biliary drainage for hilar cholangiocarcinoma.

Authors:  Hong-Ming Tsai; Chiao-Hsiung Chuang; Xi-Zhang Lin; Chiung-Yu Chen
Journal:  World J Gastroenterol       Date:  2009-11-07       Impact factor: 5.742

8.  Surgery for extrahepatic cholangiocarcinoma: predictors of survival.

Authors:  J J Kloek; F J Ten Kate; O R C Busch; D J Gouma; T M van Gulik
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

9.  Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21.

Authors:  E Friend; G Yadegarfar; C Byrne; C D Johnson; O Sezer; S Pucciarelli; S P Pereira; W-C Chie; A Banfield; J K Ramage
Journal:  Br J Cancer       Date:  2011-01-25       Impact factor: 7.640

10.  ERCC1 Can Be a Prognostic Factor in Hilar Cholangiocarcinoma and Extrahepatic Bile Duct Cancer, But Not in Intrahepatic Cholangiocarcinoma.

Authors:  Kyun Woo Park; Eun-Seon Jung; Dong-Gu Kim; Young-Kyung Yoo; Tae-Ho Hong; In Seok Lee; Yoon Ho Koh; Ji-Hoon Kim; Myung Ah Lee
Journal:  Cancer Res Treat       Date:  2013-03-31       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.